SCHEMBL560183

SCHEMBL560183

C1=C\CCCC\C=C/1.CC1=C(C)C(C)(C)C([Ru]Cl)=C1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002779 0.85
SCHEMBL2542068 0.85
SCHEMBL3700202 0.81 CTSD (0.31)
SCHEMBL3009512 0.74
SCHEMBL21796153 0.73
SCHEMBL10606591 0.73
Hydrochloric Acid SCHEMBL2898083 0.72
Hydrochloric Acid SCHEMBL19639026 0.72
SCHEMBL2996816 0.69
SCHEMBL3007177 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695260-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2026-02-18 EP disclosed
EP-4651955-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2025-11-26 EP disclosed
WO-2025202922-A1 IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2025-10-02 WO disclosed
US-20250066378-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2025-02-27 US disclosed
US-12162887-B2 Spiro-oxazolones HOFFMANN-LA ROCHE INC. (US) 2024-12-10 US disclosed
US-20240383922-A1 KRAS Modulating Compounds GILEAD SCIENCES, INC. 2024-11-21 US disclosed
WO-2024215754-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2024-10-17 WO disclosed
US-12109269-B2 Carborane hydroxamic acid matrix metalloproteinase inhibitors and agents for boron neutron capture therapy LOYOLA UNIVERSITY OF CHICAGO (US) 2024-10-08 US disclosed
WO-2024153947-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2024-07-25 WO disclosed
US-11964960-B2 Pyridinone- and pyridazinone-based compounds and uses thereof CORNELL UNIVERSITY (US) 2024-04-23 US disclosed
EP-3083633-A1 SPIRO-OXAZOLONES F.HOFFMANN-LA ROCHE AG (CH) 2016-10-26 EP disclosed
WO-2015091411-A1 SPIRO-OXAZOLONES F. HOFFMANN-LA ROCHE AG (CH) 2015-06-25 WO disclosed
US-20140038936-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED 2014-02-06 US disclosed
US-8466288-B2 Isoindolinone inhibitors of phosphatidylinositol 3-kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-18 US disclosed
WO-2013041106-A1 SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS 11CO FOR CARBONYLATION REACTIONS IN THE PREPARATION OF RADIOPHARMACEUTICALS FOR PET IMAGING AARHUS UNIVERSITET (DK) 2013-03-28 WO disclosed
EP-2516417-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE Vertex Pharmaceuticals Incorporated (US) 2012-10-31 EP disclosed
US-20120202784-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-09 US disclosed
US-20120040950-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
US-20120035217-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-02-09 US disclosed
WO-2011087776-A1 ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 WO disclosed